Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial.
暂无分享,去创建一个
T. Ide | N. Izumi | H. Mo | O. Yokosuka | P. Pang | M. Mizokami | M. Omata | T. Takehara | Y. Ueno | H. Toyoda | H. Mochizuki | K. Nirei | T. Umemura | J. McHutchison | H. Enomoto | H. Yatsuhashi | N. Sakamoto | W. Symonds | F. Ikeda | M. Korenaga | N. Toda | K. Garrison | M. Yanase | T. Genda | K. Nakane | S. Knox | B. Gao | Yoichi Nishigaki | Juan Betular | Akinobu Ishizaki | Masakatsu Omote | A. Ishizaki | Takuya Genda